再生牙髓治疗在牙髓坏死未成熟恒牙中的疗效:系统综述与网状Meta分析
该研究通过检索PubMed、Cochrane、Web of Science和Embase(截至2022年8月)共3021篇文章,纳入9项随机对照试验进行网状Meta分析,评估不同支架材料对牙髓坏死未成熟恒牙再生牙髓治疗(RET)的效果。结果显示,在术后1-12个月内,富血小板血浆(PRP)和富血小板纤维蛋白(PRF)在主要和次要结局上均取得最高成功率;超过12个月随访时,胶原或碱性成纤维细胞生长因子(bFGF)联合血凝块支架的次要结局成功率最高。证据质量极低至低,提示PRP和PRF仅在短期显示优势,长期效果尚不明确。
要点
- PRP和PRF在RET术后1-12个月的主要和次要结局上成功率最高。
- 超过12个月随访时,胶原或bFGF联合血凝块支架的次要结局成功率最高。
- 证据质量极低至低,PRP和PRF的长期疗效尚不明确。
核心结论
- 有限证据表明PRP和PRF在短期(12个月内)成功,但长期效果未显示优势。
- 该信息价值在于建议未来随机试验优先纳入这两种材料。
研究设计与样本
- 系统综述与网状Meta分析,检索PubMed、Cochrane、Web of Science和Embase截至2022年8月,共3021篇文章。
- 纳入9项随机对照试验进行定量合成,采用网状Meta分析估计治疗效应。
- 使用修订版Cochrane偏倚风险工具评估质量,GRADE方法评估证据质量。
主要发现
- 共识别6种干预:血凝块支架(BC)、BC+bFGF、BC+胶原、血小板团、PRP和PRF。
- PRP支架在6-12个月根长增加最大(MD=4.2;95%CrI 1.2至6.8;SUCRA=89.0%,极低置信度)。
- PRP或PRF在1-6个月和6-12个月的主要和次要结局成功率最高。
- 超过12个月随访,BC+胶原或BC+bFGF的次要结局成功率最高。
关键数值与推荐
- 主要结局为临床和影像学愈合;次要结局为根尖闭合、根长和根壁厚度增加。
- PRP在6-12个月根长增加MD=4.2(95%CrI 1.2至6.8),SUCRA=89.0%,极低置信度。
- 证据质量极低至低,提示PRP和PRF在术后12个月内比传统血凝块支架成功率更高。
临床怎么用
- 对于牙髓坏死的未成熟恒牙,RET短期(12个月内)可优先考虑PRP或PRF支架。
- 超过12个月随访时,可考虑胶原或bFGF联合血凝块支架以改善次要结局。
- 临床决策应结合极低至低证据质量,充分告知患者长期疗效不确定性。
局限性
- 纳入研究数量有限(9项),证据质量极低至低。
- PRP和PRF的长期成功率未显示优势,结论限于短期。
- 未来需优先纳入PRP和PRF的随机试验以验证长期效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of this study was to assess which treatment modality regarding scaffold selection for immature permanent teeth with pulpal necrosis will be the most successful for regenerative endodontic treatment (RET). METHODOLOGY: PubMed, Cochrane, Web of Science and Embase, and additional records until August 2022 were searched providing a total of 3021 articles, and nine of these articles were included for quantitative synthesis. The reviewers selected eligible randomized controlled trials and extracted pertinent data. Network meta-analysis was conducted to estimate treatment effects for primary outcomes (clinical and radiographic healing) and secondary outcomes (apical closure, root length and root wall thickness increase) following RET [mean difference (MD); 95% credible interval (CrI) and surface under the cumulative ranking curve (SUCRA)]. The quality of the included studies was appraised by the revised Cochrane risk of bias tool, and the quality of evidence was assessed using the GRADE approach. RESULTS: Six interventions from nine included studies were identified: blood clot scaffold (BC), blood clot scaffold with basic fibroblast growth factor, blood clot scaffold with collagen, platelet pellet, platelet-rich plasma (PRP) and platelet-rich fibrin (PRF). The PRP scaffold showed the greatest increase in root lengthening at 6-12 months (MD = 4.2; 95% CrI, 1.2 to 6.8; SUCRA = 89.0%, very low confidence). PRP or PRF achieved the highest level of success for primary and secondary outcomes at 1-6 and 6-12 months. Blood clot scaffold (with collagen or combined with basic fibroblast growth factor (bFGF)) achieved the highest level of success for secondary outcomes beyond 12 months follow-up. A very low to low quality of evidence suggests that both PRP and PRF exhibit the greatest success evaluating primary and secondary outcomes within 12 months postoperatively compared to the traditional blood clot scaffold protocol. CONCLUSION: Limited evidence suggests both PRP and PRF exhibit success in the short-term, not long-term. The value of this information stems in its recommendation for future randomized trials prioritizing both of these materials in their protocol.
引用
- Sabeti M, Ghobrial D, Zanjir M, et al. Treatment outcomes of regenerative endodontic therapy in immature permanent teeth with pulpal necrosis: A systematic review and network meta-analysis. Int Endod J. 2023. PMID: 37966465. doi:10.1111/iej.13999
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。